Peptides for Skin: Can One Serum’s Results Apply to Another?

A wrinkle study can make an ingredient sound settled when the useful answer is much narrower. For peptides for skin, results from one finished serum do not establish that another serum—or another route of exposure—will produce the same change. The ingredient name cannot do all the paperwork. So what survives when we look past the name and examine the actual formulation?

GHK-Cu, a short peptide bound to copper, offers a concrete example. The selected evidence includes a small facial study, experiments in skin cells and removed human skin, and a test of how much peptide remained in skin. Each answers a different question. Together, they explain why copper peptides attract research interest and why confidence in transferable visible benefits remains low. They cannot supply a ranking of the best peptides or a prediction for another product carrying the same ingredient.

Research Confidence

★★☆☆☆ — Limited confidence in visible benefits transferring between GHK-Cu formulations. The selected human study enrolled middle-aged women and used three-dimensional wrinkle imaging over eight weeks. Its comparison did not isolate the peptide from its carrier; the other scientific papers measured laboratory responses or delivery rather than facial outcomes.

Study Snapshot

• Study type: Preliminary double-blind, split-face human facial study
• Participants: 40 women aged 40–65; 39 completed
• Duration: Eight weeks
• Measured: Wrinkle volume and depth using three-dimensional imaging
• Found: Mean wrinkle-volume changes of −24.1% with experimental serum versus −15.0% with vehicle
• Funding: Snowberry New Zealand and Callaghan Innovation; sponsor noninvolvement declared

Why This Matters: Peptides for Skin Are Studied as Formulations

Facial texture is something a person sees in a mirror. A collagen signal is something researchers measure in a biological experiment. When the question is “what do peptides do for skin?”, those answers deserve separate space.

Someone comparing two ingredient lists might reasonably expect the shared peptide to make the products comparable. But a finished serum also contains ingredients that affect its texture, stability and contact with skin. Even the comparison serum can change what the trial means.

A useful discussion about a cosmetic claim therefore starts with the exact formulation and the outcome measured: a laboratory signal, an instrument-detected change, or a visible difference people noticed. The broader guide to understanding research peptides provides context for that distinction. For facial skin, the question becomes especially concrete: what actually changed on a face?

The facial study measured a serum, side by side

The strongest human evidence here puts the same person's two facial sides into the comparison. In Badenhorst and colleagues’ 2016 preliminary human study, participants received a GHK-Cu nanocarrier serum on the right side and a comparison product on the other. “Double-blind” means the study concealed treatment identities from participants and evaluators.

The experimental topical serum was applied twice daily; its GHK-Cu concentration was unreported. Participants were assigned between comparison groups, but the experimental side stayed fixed. One comparator was a serum lacking both the peptide and its carrier. The other was a commercial Matrixyl-containing product with palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.

Against the peptide-and-carrier-free serum, average wrinkle-depth changes were −20.3% versus −15.3%. Both sides changed. Against the commercial comparator, superiority for depth was not statistically established: P=0.0577. That result leaves the claimed difference unresolved rather than demonstrating equality.

The percentages describe the surface features detected by an instrument; they do not mean a face looked that percentage younger. The instrument, commendably, made no attempt to guess anyone's birthday.

One participant withdrew after reactions on both facial sides. That account cannot identify which ingredient caused the reactions.

Collagen signals ask a different question

Skin biology supplies a reason to investigate GHK-Cu. It also supplies several ways to measure something other than wrinkles. Terms such as “signal peptides for skin” describe a proposed biological role, not a shared clinical result for every ingredient in the category.

Jiang and colleagues’ 2023 laboratory study tested human skin cells and explants—removed skin kept alive in laboratory conditions. The combination contained 30 μg/mL GHK-Cu and 270 μg/mL low-molecular-weight hyaluronic acid; single-ingredient conditions used 300 μg/mL. Explants received four daily treatment cycles followed by 72 hours in culture. There were six replicates per condition, not six volunteers.

Compared with untreated, ultraviolet-exposed and single-ingredient conditions, the combination increased collagen-IV signals. Collagen IV helps form a supporting layer between skin compartments. Responses involving collagen I and VII were weaker than some single-ingredient responses.

Adding ingredients did not give every collagen type the same enthusiasm. These were changes in gene activity and tissue staining, not observations of smoother faces.

The carrier-free control in the facial study is the decisive weakness for ingredient-level claims: removing both carrier and peptide means the result cannot fairly be credited to GHK-Cu alone. The laboratory findings make that distinction more consequential, because changing the combination changed the response.

Getting into skin is another test entirely

A peptide must reach relevant skin tissue before a local biological effect is plausible. Dymek and colleagues’ 2025 laboratory formulation study examined that earlier step using excised human abdominal skin, rather than volunteers’ faces.

The team compared aqueous GHK-Cu with anionic liposomes—small lipid-walled carriers. Their preparation used peptide solution at 0.5 mg/mL; the permeation methods did not separately specify every exposure detail. During a 24-hour experiment, they measured peptide remaining in skin and reaching fluid beyond it, with measurements in triplicate.

Skin retention was 11.28 ± 1.61 μg/cm² with liposomes versus 11.85 ± 3.64 μg/cm² without. The difference was not statistically significant. No peptide was detected in the receiving fluid. Under these conditions, the carrier did not demonstrate greater retention.

The investigation now has three distinct stopping points: a finished serum changed measured facial features; an ingredient combination changed laboratory collagen signals; and a different carrier failed to increase skin retention. These are separate experiments, not a development programme that proved the same outcome three times. For topical peptides for skin, even reaching tissue and changing its appearance require different tests.

What This Tells Us About Women Specifically: Midlife Was Studied, Menopause Was Not

All participants in the facial study were women. That makes it relevant to midlife readers, but menopausal status and hormone therapy were not reported. The paper cannot separate responses before, during or after menopause.

Men were not enrolled, so applicability to men remains unanswered. The laboratory papers did not provide sex-specific results or independent donor counts that would resolve that gap.

For someone exploring ageing-related research, the distinction matters: an age range describes who took part. It does not reveal whether hormonal stage influenced the response.

Research Use And Availability

Nuforme supplies GHK-Cu as a research material in Canada, designated for research use only, not human consumption. It is not the finished serum studied in volunteers. Health Canada’s April 9, 2026 advisory names GHK-Cu among unauthorized injectable peptide products and states that research-use-only labelling does not exempt products from regulatory requirements. That advisory is not a product-by-product assessment of cosmetic serums.

Final Thoughts: Another Serum Needs Its Own Evidence

A different GHK-Cu serum needs evidence tied to its own formulation before equivalent facial results can be expected. The human signal is worth investigating, but the edges are concrete: a small, short, industry-funded study; fixed treatment sides; an unreported peptide concentration; and no identical-carrier control. Persistence after treatment ended was not established.

The laboratory papers add no clinical safety follow-up, and their independent donor counts were unreported. None of these experiments establishes cosmetic outcomes from injectable GHK-Cu.

Confidence would rise with independent, longer replication using randomly assigned facial sides, an identical carrier without peptide, complete safety reporting, and visible outcomes alongside imaging. The useful finding remains attached to the serum and question actually tested.